Switzerland-based Vifor Pharma, part of the Galenica group (SIX: GALN), has received US Food and Drug Administration (FDA) approval for Velphoro (sucroferric oxyhydroxide) for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
A New Drug Application for Velphoro, previously known as PA21 (iron(III)-oxyhydroxide), was submitted in February. US approval was based on a pivotal Phase III study, which met its primary and secondary endpoints. The study demonstrated that Velphoro successfully controls hyperphosphatemia with fewer pills than sevelamer carbonate, the current standard of care in patients with CKD on dialysis. The average daily dose to control hyperphosphatemia was 3.3 pills per day after 52 weeks.
Lowers pill burden for patients
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze